Search
Search
AAO: 2026
Show Description +
Dr. Maturi highlights key takeaways from the phase 2 ArMaDa trial of OCU410 (Ocugen), a modifier gene therapy for GA. The 12-month topline safety and efficacy data show positive findings with the medium dose, which is moving into phase 3 trials.
Posted: 10/15/2026
Dr. Maturi highlights key takeaways from the phase 2 ArMaDa trial of OCU410 (Ocugen), a modifier gene therapy for GA. The 12-month topline safety and efficacy data show positive findings with the medium dose, which is moving into phase 3 trials.
Posted: 10/15/2026
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2026.
Please log in to leave a comment.